BeBetter Med Inc. is a biopharmaceutical firm focused on the research and development of breakthrough medications in vital therapeutic fields such as oncology, autoimmune diseases, and metabolic disorders. Established in 2012 in Guangzhou by Professor Changgeng Qian alongside a cadre of global returnees, BeBetter Med utilizes its proprietary technology platform to formulate groundbreaking pharmaceutical solutions that balance clinical effectiveness with practical utility. Guided by the ethos of "Committed to Innovation, Striving for Excellence," the company is unwavering in its commitment to independent research and to generating globally patented, safe, and effective medications.
Comprising the leadership tier of BeBetter Med Inc. is an illustrious collective of professionals, including nationally honored experts, accomplished entrepreneurs, and exceptional scientists. Together, they offer a wealth of experience in both domestic and global pharmaceutical development as well as in corporate management. Team members have been consistently honored as preeminent technological talents in the Guangzhou Development Zone and have garnered inclusion in the prestigious Guangdong "Pearl River Talent Plan" as innovative entrepreneurs.
In recognition of its contributions, BeBetter Med has been conferred the status of a Guangdong Postdoctoral Innovation Practice Base and is identified as a Guangdong Provincial New Drug Discovery and Industrialization Engineering Technology Research Center. Additionally, the company has gained acclaim as an emergent "Future Unicorn" and holds the distinction of being a "High-Tech and High-Skill" enterprise in Guangzhou.
Ph.D., M.D. Professor of Central South University, former senior vice president in drug discovery, Curis Inc. in the US. Involved in research and development of FDA-approved FIC drugs Campath, Velcate, Entyvio, and Erivedge. Holds over 50 US and 20 Chinese granted patents and has more than 30 academic papers. Honored as the "Scientific Chinese of the Year (2013)".
M.S. in Medicinal Chemistry from Shanghai Medical University (now Fudan University), Visiting Scholar (Postdoctoral research) at the Department of Chemistry, University of Virginia, former Adjunct Professor of Central South University, former Vice President of Curis, Inc. in the United States. Holds more than 60 issued US patents and more than 20 granted Chinese patents, and published more than 40 PCT patents and more than 20 academic papers.
Ph.D., Professor of Sun Yat-Sen University, former senior scientist of Duke University. Published more than 40 academic papers in top journals including Nature, Nature Med, Cell Res, Mol Cell.
M.S. Central South University, Former senior director of clinical operations at Tiger Medicine, has over 15 years of experience in clinical study management and team management., successfully led several clinical trials on innovative drugs.
Ph.D., published several SCI papers including Cancer Research and elife. Holds 8 patents and responsible for preclinical evaluation of several innovative drugs.
LLM, prior to joining Bebetter Med, served as legal adviser and representative of WIPO Coordination Office at the UN, head of compliance and risk control at Hiyield Investment Group, and attorney at China Sinda IP.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号
